AUTO3
AUTO3-DB1
Phase 2 mab terminated
Quick answer
AUTO3 for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 2 program (mab) at Autolus Therapeutics plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Autolus Therapeutics plc
- Indication
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated